You searched for morphosys - Page 9 of 11

News and Trends 12 Jul 2016

Which European Biotechs made it to the Billion-Euro Club in 2016?

Europe has a lot of successful Biotech companies, but which of those are worth a billion euros or more? I did a previous version of this article last year and now I explore how these have evolved. Just 9 European Biotech companies (private and public) are worth over one billion right now. Many of these were present last year. For […]

July 12, 2016 - 6 minutesmins - By Philip Hemme

biogeneration capital ventures finance money fund biotech medtech

News and Trends 5 Jul 2016

The Fund behind the ‘Biggest Private Exit Ever’ to Raise another €50M

BioGeneration Ventures has had its first close of a new venture capital fund, ‘BioGeneration Capital Fund III’, for novel diagnostic, medtech and therapeutic biotechs in Europe. BioGeneration Ventures (BGV) is based in Naarden (Netherlands) and manages funds investing in Netherlands, Belgium and Germany. Some of its biotech porfolio companies have included Dezima Pharma (acquired by Amgen from […]

July 5, 2016 - 2 minutesmins - By Dani Bancroft

morphosys thrombosis phaseI novartis hucal

News and Trends 4 Jul 2016

Novartis delivers German Biotech’s 12th Antibody to Clinics

MorphoSys keeps up its impressive productivity in feeding pipelines. Its 12th antibody in its Novartis collaboration has just reached clinical development. After presenting results for two of its wholly-owned candidates at ASCO 2016 (you can get an insider look into ASCO from the team), MorphoSys is receiving good news on the collaborations’ front. One of the […]

July 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 28 Jun 2016

What’s the Truth about Gender Diversity in Biotech?

The diversity debate in biotech has always been there. In the month of Pride and after LifeSci’s party scandal at JPMorgan 2016, I was wondering what’s the real situation about diversity in biotech? And what could be the solutions? Haven’t you heard about the LifeSci’s party scandal? In short: the editor of BioCentury Karen Bernstein […]

June 28, 2016 - 5 minutesmins - By Philip Hemme

Best in Biotech 22 Jun 2016

11 Biotech Leaders you should meet in Munich

I guess you’ve read some of our tops lately (VCs, Paris, Unicorns). Those were mainly about specific companies or regions. Now, we wanted to try a new format and focus on people instead. For this first edition, we decided to focus on Munich, one of Europe’s top biotech regions. I asked some biotech leaders in Munich […]

June 22, 2016 - 5 minutesmins - By Philip Hemme

asco biotech morphosys cancer chicago 2016 researh pharma

News and Trends 9 Jun 2016

How was it inside the ‘World Most Important Cancer Meeting’ of the Year?

Every year by the end of May/beginning of June, up to 30,000 of healthcare professionals head to Chicago to discuss the most recent advancements in Cancer treatments. Here, the MorphoSys team, which included Claudia Gutjahr-Löser and Jochen Orlowski, give you a sneak-insiders look into one of the most essential Cancer conferences of the year… You can also […]

June 9, 2016 - 4 minutesmins - By Dani Bancroft

News and Trends 8 Jun 2016

12 European Biotechs which ‘stole the show’ at World most Important Cancer Meeting

Pharma and Biotech from every corner flocked to Chicago for the beginning of June. Why? It’s where one of the biggest oncology events happens – the ASCO Annual Meeting 2016. Shortly after the AACR annual meeting (with presentations from several European Biotechs), it’s time for the ASCO annual meeting. Hosted by the American Society of Clinical […]

June 8, 2016 - 7 minutesmins - By Denise Neves Gameiro

zurich biotech octapharma ehtz switzerland

News and Trends 7 Jun 2016

Zurich is not all about Money – here are 9 Biotechs proving it!

The biggest city in Switzerland, Zurich, is one of Europe’s top financial centers and home to the SIX Swiss Exchange (SWX). It’s also one of the most expensive cities in Europe to live in (as my Swiss colleague Claire could confirm). With so much money nearby, how does the local Biotech ecosystem looks like? The biggest Biotech/mid-size Pharma in […]

June 7, 2016 - 5 minutesmins - By Denise Neves Gameiro

blood cancer disease model, multi-omics, CAR-T, oncology

News and Trends 28 May 2016

It’s Blood Cancer Day, how is Biotech fixing it?

Today is the World Blood Cancer Day, an event to show solidarity to patients and raise awareness for the need of better therapies to treat these cancers – which are still often deadly. Blood cancers can affect different type of cells in the blood. Because these cells are so close to the circulatory and immune system, […]

May 28, 2016 - 4 minutesmins - By Denise Neves Gameiro

gsk morphosys hand osteoarthritis rheumatoid

News and Trends 19 Apr 2016

GSK goes to phase II with German Antibody for Inflammatory Diseases

GSK has started a phase II trial for inflammatory hand osteoarthritis, with a candidate originally from MorphoSys‘ antibody library. GSK, a big UK Pharma, has announced the start of a phase II study to evaluate the efficacy and safety of its candidate, GSK3196165. The trial will enroll 40 patients with hand osteoarthritis – a condition that damages […]

April 19, 2016 - 2 minutesmins - By Denise Neves Gameiro

Vibiosphen biotech infectious disease pierre fabre

News and Trends 15 Apr 2016

Pierre Fabre partners for Open Innovation in Infectious Disease

Pierre Fabre has a new partnership for its Open Innovation programme based on an extensive plant library. It will now count with VibioSphen to develop new phyto-chemicals to fight infectious diseases. Pierre Fabre is the 3rd largest Pharma in France, employing over 10,000 people and generating revenues of over €2Bn. Lately, this mid-sized company made efforts […]

April 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

Europe VC top investors biotech life sciences finance

Best in Biotech 12 Apr 2016

18 of the Best European VCs for Biotech in 2016

As Genentech is celebrating its 40th Birthday, it is also the 40th birthday of Biotechnology and the 40th birthday of Biotech Venture Capitalists. These risk investors are deeply linked to any venture successes. And although Europe definitely has fewer than in the US, there’s still a significant amount of influence and wealth on this side […]

April 12, 2016 - 10 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us